Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative GN
Despite slowly progressing disease in the current cohort, C3G and primary IC-MPGN create a significant clinical, economic and healthcare burden among affected patients and their families.
Authors
- Chloe Middleton‐Dalby (ORCID: https://orcid.org/0000-0001-5470-1329)
- Carly Rich (ORCID: https://orcid.org/0000-0003-4717-5855)
- Ming‐Yi Huang (ORCID: https://orcid.org/0000-0003-4574-2385)
- Lucía Quintana‐Gallardo (ORCID: https://orcid.org/0000-0002-1897-3535)
- Fernando Caravaca‐Fontán (ORCID: https://orcid.org/0000-0002-5830-9663)
- Sayna Norouzi (ORCID: https://orcid.org/0000-0001-9912-4959)
- Sarah T. Clayton (ORCID: https://orcid.org/0000-0002-9372-7174)
- Kathryn Gordon (ORCID: https://orcid.org/0000-0003-1483-0657)
- Mollie Lowe (ORCID: https://orcid.org/0009-0002-5480-0591)
- KD Fitzmaurice
Institutions
- Loma Linda University Medical Center (US)
- Loma Linda University (US)
- Research Institute Hospital 12 de Octubre (ES)
- Adelphi Group (United Kingdom) (GB)
- Apellis Pharmaceuticals (United States) (US)
- Swedish Orphan Biovitrum (Sweden) (SE)
Publication Details
- Journal
- Kidney360
- Published
- 2025-12-08
- DOI
- https://doi.org/10.34067/kid.0000001059
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00